See more : Elecon Engineering Company Limited (ELECON.BO) Income Statement Analysis – Financial Results
Complete financial analysis of BioSig Technologies, Inc. (BSGM) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of BioSig Technologies, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
- Thai Beverage Public Company Limited (TBVPY) Income Statement Analysis – Financial Results
- The Shikoku Bank, Ltd. (8387.T) Income Statement Analysis – Financial Results
- The Healing Company Inc. (THCC) Income Statement Analysis – Financial Results
- Dhanalaxmi Roto Spinners Limited (DHANROTO.BO) Income Statement Analysis – Financial Results
- OUE Limited (LJ3.SI) Income Statement Analysis – Financial Results
BioSig Technologies, Inc. (BSGM)
About BioSig Technologies, Inc.
BioSig Technologies, Inc., together with its subsidiaries, operates as medical device company. The company's proprietary product includes precise uninterrupted real-time evaluation of electrograms electrophysiology (PURE EP) system, a signal processing platform that combines hardware and software to address known challenges associated to signal acquisition that enables electrophysiologists to see signals and analyze in real-time. It also focuses on enhancing intracardiac signal acquisition and diagnostic information for the procedures of atrial fibrillation, as well as is designed to address long-standing limitations that slow and disrupt cardiac catheter ablation procedures. The company has a research agreement with University of Minnesota to develop novel therapies to treat sympathetic nervous system diseases; and a strategic collaboration with the Mayo Foundation for Medical Education and Research to develop an AI-and machine learning software solution for PURE EP systems. BioSig Technologies, Inc. was incorporated in 2009 and is headquartered in Westport, Connecticut.
Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 18.00K | 286.00K | 441.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cost of Revenue | 0.00 | 57.00K | 199.00K | 550.00K | 54.35K | 12.40K | 11.70K | 10.48K | 10.48K | 0.00 | 0.00 | 0.00 | 6.80K |
Gross Profit | 18.00K | 229.00K | 242.00K | -550.00K | -54.35K | -12.40K | -11.70K | -10.48K | -10.48K | 0.00 | 0.00 | 0.00 | -6.80K |
Gross Profit Ratio | 100.00% | 80.07% | 54.88% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Research & Development | 5.09M | 5.82M | 5.60M | 18.14M | 9.74M | 4.37M | 4.76M | 2.65M | 1.24M | 548.00K | 992.21K | 888.95K | 582.53K |
General & Administrative | 23.08M | 21.38M | 27.85M | 40.95M | 24.81M | 12.88M | 8.14M | 8.50M | 10.80M | 7.30M | 5.23M | 1.29M | 0.00 |
Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 72.41K | 0.00 |
SG&A | 23.08M | 21.38M | 27.85M | 40.95M | 24.81M | 12.88M | 8.14M | 8.50M | 10.80M | 7.30M | 5.23M | 1.36M | 484.13K |
Other Expenses | 361.00K | 293.00K | 198.00K | 94.00K | 54.35K | 12.40K | 11.70K | 10.48K | 10.48K | 15.81K | 17.06K | 0.00 | 0.00 |
Operating Expenses | 28.53M | 27.49M | 33.65M | 59.18M | 34.60M | 17.26M | 12.91M | 11.16M | 12.04M | 7.87M | 6.24M | 2.26M | 1.07M |
Cost & Expenses | 28.53M | 27.55M | 33.85M | 59.18M | 34.60M | 17.26M | 12.91M | 11.16M | 12.04M | 7.87M | 6.24M | 2.26M | 1.07M |
Interest Income | 9.00K | 3.00K | 2.00K | 45.00K | 132.75K | 10.90K | 75.00 | 1.00 | 1.30K | 11.03K | 70.06K | 124.17K | 171.00 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 10.90K | 75.00 | 1.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Depreciation & Amortization | 361.00K | 666.00K | 639.00K | 550.00K | 54.35K | 12.40K | 11.70K | 10.48K | 10.48K | 15.81K | 17.06K | 10.02K | 6.80K |
EBITDA | -28.15M | -26.97M | -33.21M | -58.63M | -34.42M | -17.25M | -13.11M | -10.73M | -9.45M | -7.85M | -6.22M | -2.25M | -1.14M |
EBITDA Ratio | -156,394.44% | -9,430.77% | -7,656.69% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Operating Income | -28.51M | -27.27M | -33.41M | -59.18M | -34.60M | -17.26M | -12.91M | -11.16M | -12.04M | -7.87M | -6.24M | -2.26M | -1.07M |
Operating Income Ratio | -158,400.00% | -9,533.22% | -7,576.19% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Total Other Income/Expenses | -178.00K | 3.00K | 555.00K | 44.00K | 133.20K | 10.90K | 210.54K | -422.91K | 2.58M | -604.80K | -3.57M | -124.17K | -77.76K |
Income Before Tax | -28.69M | -27.26M | -32.86M | -59.14M | -34.47M | -17.25M | -12.70M | -11.59M | -9.46M | -8.47M | -9.80M | -2.39M | -1.15M |
Income Before Tax Ratio | -159,388.89% | -9,532.17% | -7,450.34% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Income Tax Expense | 0.00 | 9.00K | -1.49M | -6.97M | -549.05K | 21.79K | -210.54K | 422.91K | -2.58M | 11.03K | 70.06K | 90.86K | 0.00 |
Net Income | -29.04M | -27.27M | -31.36M | -52.17M | -33.92M | -17.25M | -12.70M | -11.59M | -9.46M | -8.47M | -9.80M | -2.48M | -1.15M |
Net Income Ratio | -161,338.89% | -9,535.31% | -7,111.56% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
EPS | -3.95 | -6.33 | -9.36 | -18.70 | -16.39 | -11.89 | -12.42 | -14.86 | -16.77 | -21.95 | -29.94 | -0.76 | -4.43 |
EPS Diluted | -3.95 | -6.33 | -9.36 | -18.70 | -16.39 | -11.89 | -12.42 | -14.86 | -16.77 | -21.95 | -29.94 | -0.76 | -4.43 |
Weighted Avg Shares Out | 7.35M | 4.31M | 3.35M | 2.79M | 2.07M | 1.45M | 1.02M | 779.63K | 564.12K | 386.01K | 327.51K | 3.26M | 266.00K |
Weighted Avg Shares Out (Dil) | 7.35M | 4.31M | 3.35M | 2.79M | 2.07M | 1.45M | 1.02M | 779.63K | 564.12K | 386.01K | 327.51K | 3.26M | 266.00K |
BioSig Regains Compliance with Nasdaq's Minimum Bid Price Requirement
BioSig Technologies' Common Stock to Resume Trading on the NASDAQ Exchange, Wednesday, October 23, 2024 After Its Successful Appeal to the NASDAQ Panel
BioSig Technologies Announces Intent to Acquire the Assets of Neuro-Kinesis Corporation
BioSig Technologies Appoints Mr. Ferdinand Groenewald to Position of Interim Chief Financial Officer and Principal Accounting Officer
BioSig Announces Closing of $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
BioSig Technologies Chief Executive Officer Mr. Anthony Amato Issues the Following Letter to Shareholders
BioSig Technologies, Inc. Announces New Appointments to its Now Fully Constituted Board of Directors, which is Comprised of 5 Board Members, 3 Independent
BioSig Technologies, Inc. Appoints Mr. Anthony Amato to Position of Chief Executive Officer, Effective Immediately
BioSig Engages Consulting Firm for Business Model Strategies
BioSig Announces Reduction of its Workforce
Source: https://incomestatements.info
Category: Stock Reports